Quintiles and dabl Limited, a provider of centralised ambulatory blood pressure measurement (ABPM) have now entered into a strategic alliance that significantly enhances the former’s suite of offerings in cardiovascular safety assessment.

Through the alliance, Quintiles’ customers worldwide will have access to dabl’s round-the-clock ABPM services to enhance the safety and efficacy of global clinical trials across the entire trial lifecycle.

“dabl’s scientific leadership and data management techniques are setting new industry standards and complement Quintiles’ pioneering cardiac safety solutions,” said Dr Deepa Desai, executive director, Cardiac Safety Services, Quintiles.

“Together we can improve understanding of drug-induced blood pressure responses and help our customers improve trial participant safety, manage risk, and improve efficiency,” she added.

The US FDA and other regulatory agencies are requiring assessment of 24-hour blood pressure profiles for blood pressure-lowering drugs. In addition, there is also an increased focus on how non-cardiovascular drugs affect blood pressure. The web-based dabl ABPM system automatically checks data in accordance with the study protocol. It generates alerts about safety and enrollment issues and provides real-time access to clinical data and progress reports.

Professor Eoin O’Brien, medical director, dabl, said that accuracy of circadian measurement, speed and excellence in interpreting data have never been more important in the clinical trial process. Bio-pharma companies will be able to make faster and more confident decisions about the cardiovascular effects of their compounds with the combination of Quintiles’ therapeutic expertise and dabl’s proprietary technology and excellence in providing haemodynamic profiles.

“This alliance with Quintiles is another milestone in our development, particularly in our rapidly growing Global Clinical Trial Division,” said W J “Bill Rickard, chief executive officer, dabl.

Quintiles is the world’s leading provider of biopharmaceutical services with  a network of more than 27,000 professionals working in over 80 countries. The Dublin-based dabl’s scientific research team has been responsible for many ABPM research breakthroughs and have authored many of the current hypertensive guidelines and standards.